Effect of Hridyarnava Rasa and Haritkyadi Yoga in Stable Coronary Artery Disease (CAD)

Phase 3

• Conditions: Health Condition 1: I259- Chronic ischemic heart disease, unspecified

• Registration Number: CTRI/2023/04/051670
• Lead Sponsor: Central Council for Research in Ayurvedic Sciences (CCRAS) (Ministry of AYUSH Govt. of India)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Patients of either sex aged 35-75 years

2.Subjects diagnosed with stable coronary artery disease (CAD) having GLS value poor than -14

3.Patients willing to participate in the study for 30months.

Exclusion Criteria

1.Subjects with history of Coronary Artery Bypass Grafting (CABG) and percutaneous trans luminal coronary angioplasty (PTCA);

2.Subjects with symptomatic CAD (Chest pain at Rest);

3.Subjects with recent acute coronary syndrome (within last 3 months);

4.Subjects with congestive cardiac failure;

5.Subjects with anomalies of coronary arteries, valvular heart disease, cardiac arrhythmias;

6.Subjects with uncontrolled hypertension (BP = 180/100 mm Hg);

7.Subjects with history of CVA/Stroke (within six months)

8.Subjects with history of coagulation disorders

9.Subjects with History of uncontrolled Diabetes Mellitus with HbA1c = 10

10.History of Pulmonary dysfunction, psychiatric illness, HIV infection or any other comorbidities

11. Subjects with BMI = 35 kg/m2

12.Subjects with history of active malignancy;

13.Subjects with Serum TSH =10µIU/ml with or without medication.

14.Subjects with serum creatinine level = 1.2 mg/dL, chronic kidney disease (GFR < 60 ml/min),

15.Subjects with abnormal Liver Function Test (LFT) with values more than two times the upper limit of normal;

16.Subjects on corticosteroids, immunosuppressive drugs or any other medication which from the investigator’s viewpoint may not be suitable for the study participation;

17.Subject with history of chain smoking, alcohol or substance abuse

18.Subjects with suspected hypersensitivity to any of the ingredients of study medication;

19.Subjects with concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent;

20.Female subjects who are pregnant or lactating or planning to conceive during the study period. Females who are not ready to use acceptable contraceptive methods during the course of study;

21.Any condition that the investigator thinks may jeopardise the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified